NCOG-47. SYMPTOMATOLOGY OF PRIMARY BRAIN TUMOR PATIENTS AT CLINICAL TRIAL INITIATION: SNAPSHOT FROM THE NCI NOB-NATURAL HISTORY STUDY

Abstract Clinical trial endpoints include response/survival, but also treatment tolerance and clinical benefit. Few reports exist on the frequency type of disease-related symptoms functions treatment-associated symptomatic toxicities at initiation. The MD Anderson Symptom Inventory-Brain Tumor self-reports from patients baseline a initiation were retrospectively evaluated for presence severe ratings ( ≥ 7 symptom, 6 interference) Reeve's toxicity (TS) (pain, fatigue, nausea, insomnia, anxiety, dyspnea, anorexia, depression, vomiting, neuropathy, constipation, diarrhea) RANO-COA Collaborative core (DRS) perceived cognition, difficulty communicating, seizure, physical function, role/social functioning). A total 137 assessments 132 10 trials evaluated. Patients primarily white (82%) males (67%), with median age 48 years (range: 19-76), initiating recurrent (86%) high grade (95%) tumor. Thirty-six percent reported TS 1-9) 48% DRS 1-8), both 2 symptoms. All 12 as (TS range: 3%-23%); 1%-25%); most common fatigue (23%), insomnia (12%), anxiety (10%) TS, function-work (25%), function-walking (24%), function-usual activity (20%) DRS. Those ≤ 4 weeks since recurrence more frequently (53%) or (62%). if closely followed previous (0-4 weeks: 45%). Baseline symptom occurrence functional limitations their severity are critical to understanding tolerability For adjustments warranted anticipated toxicities. High necessitates management supportive care approaches entering promotes improvement measures along traditional such tumor reduction prolongation survival outcomes.